Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.71 |
| ▸ | POLB | P06746 | 2/20 | 0.71 |
| ▸ | ATM | Q13315 | 1/20 | 0.61 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.54 |
| ▸ | ABCC1 | P33527 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | UBE2M | P61081 | 1/20 | 0.45 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CASR | P41180 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | CCR5 | P51681 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5533361 | 0.86 | POLB (0.65) | RAB9APOLBATMRXFP1ABCC1 | |
| SCHEMBL5534712 | 0.85 | RAB9A (0.64) | RAB9APOLBATMABCC1KMT2A | |
| SCHEMBL11779080 | 0.81 | TP53 (0.62) | RXFP1TP53CASR | |
| SCHEMBL7618240 | 0.80 | RXFP1 (0.50) | RAB9APOLBRXFP1KMT2AUBE2M | |
| SCHEMBL11599130 | 0.77 | ATM (1.00) | RAB9APOLBATMABCC1KMT2A | |
| SCHEMBL5534327 | 0.75 | RAB9A (0.65) | RAB9APOLBATMABCC1KMT2A | |
| SCHEMBL11738389 | 0.74 | L3MBTL1 (0.59) | RAB9APOLBRXFP1UBE2MDCUN1D1 | |
| SCHEMBL11631147 | 0.74 | ATM (0.67) | RAB9APOLBATMABCC1KMT2A | |
| SCHEMBL7612008 | 0.73 | KMT2A (0.60) | RAB9APOLBATMRXFP1KMT2A | |
| SCHEMBL14521785 | 0.73 | TRPV1 (0.53) | RXFP1KMT2AMEN1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070010671-A1 | Novel quinazoline derivatives and methods of treatment related to the use thereof | ARENA PHARMACEUTICALS, INC. | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010671-A1 | Novel quinazoline derivatives and methods of treatment related to the use thereof | MCHR1, GPR119, MCHR2 | RAB9A 902/4885POLB 4518/4885ATM 2072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.